This Article Full Text Free Full Text (PDF) Free All Versions of this Article: chest.06-2493v1 132/3/780    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by de Perrot, M. Articles by Granton, J. T. Search for Related Content PubMed PubMed Citation Articles by de Perrot, M. Articles by Granton, J. T.

Evaluation of Persistent Pulmonary Hypertension After Acute Pulmonary Embolism^*

^* From the Division of Thoracic Surgery, Toronto General Hospital, University of Toronto, Toronto, ON, Canada.

Correspondence to: Marc de Perrot, MD, MSc, Division of Thoracic Surgery, Toronto General Hospital, 9N-961, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada; e-mail: marc.deperrot{at}uhn.on.ca

Abstract

Background: Better knowledge of the evolution of persistent pulmonary hypertension after acute pulmonary embolism (PE) is required to optimize the indication and timing of pulmonary endarterectomy (PEA).

Methods: We reviewed our experience with 17 consecutive patients demonstrated to have persistent pulmonary hypertension after acute massive (n = 1), submassive (n = 7), or recurrent PE (n = 9).

Results: After a median of 18 weeks of anticoagulation (range, 12 to 30 weeks) since the last PE, 10 patients showed residual pulmonary artery systolic pressure (PAsP) > 50 mm Hg. These patients demonstrated a significant progression in PAsP over the ensuing 6 to 12 months, from 73 ± 14 to 101 ± 26 mm Hg (p = 0.005) [mean ± SD], and eight patients were found to be suitable candidates for PEA. In contrast, among seven patients with residual PAsP from 35 to 40 mm Hg (n = 3) and 41 to 50 mm Hg (n = 4), six patients had evidence of residual perfusion defects on the ventilation/perfusion scan and CT. The PAsP did not change significantly over the ensuing 6 to 12 months, except in two patients who had new episodes of acute PE.

Conclusions: Two groups of patients can be identified based on the degree of residual pulmonary hypertension after acute PE. Patients with residual PAsP > 50 mm Hg should be evaluated for PEA since their pulmonary artery pressures will significantly progress over the ensuing 6 to 12 months despite the absence of recurrent PE. In contrast, patients with PAsP from 35 to 50 mm Hg are at risk for severe pulmonary hypertension if new PE occurs, and should therefore be closely monitored.

Key Words: acute pulmonary emboli • chronic thromboembolic pulmonary hypertension • pulmonary thromboendarterectomy